Objectives: To report on the experience with a selective prophylactic permanent pacemaker (PPx-PPM) implantation strategy in patients with pre-existing right bundle branch block (RBBB) undergoing transcatheter aortic valve replacement (TAVR). Background: Pre-existing RBBB is an independent predictor for PPM after TAVR and has been linked to increased mortality. Methods: Hospital patient flow and longer-term clinical endpoints were compared for TAVR patients with pre-existing RBBB treated in a period with and without selective PPx-PPM strategy (2013–2020). Results: A total of 260 patients were included: 170 in the early period without PPx-PPM strategy and 90 patients in the late period with selective PPx-PPM strategy. A PPx-PPM was implanted in 44% of patients in the late period. Overall, 69% versus 80% of all patients in the early versus late period ended up with a PPM (p =.06). Streamlined transfemoral TAVR was routinely used from 2017—in this series of patients, both TAVR procedural time and hospital length of stay (LoS) were significantly shorter in the late versus early period (mean procedural time: 70 vs. 83 min and LoS ≥5 days: 15% vs. 40%; p <.05). No difference in all-cause/cardiovascular mortality was observed between both strategies, whereas cardiac rehospitalization was significantly higher for patients treated in the early versus late period (hazard ratio 2.33 [1.04–5.26]; p =.042)—this mainly due to (sub)acute PPM-implantation early after discharge. Conclusions: Selective prophylactic PPM implantation in TAVR candidates with pre-existing RBBB results in shorter TAVR procedural time and hospital LoS and prevents early cardiac rehospitalization related to complete heart block.
|Journal||Catheterization and Cardiovascular Interventions|
|Early online date||14 Aug 2021|
|Publication status||Published - 1 Dec 2021|
Bibliographical noteFunding Information:
Dr. Bieliauskas has received consulting fees from Abbott, Boston Scientific and Medtronic. Dr. de Jaegere is proctor for Boston Scientific. Dr. Van Mieghem has received institutional research grants and consulting fees from Abbott, Boston Scientific, Medtronic and PulseCath BV. Dr. Søndergaard has received institutional research grants and consulting fees from Abbott, Boston Scientific, and Medtronic. Dr. De Backer has received institutional research grants and consulting fees from Abbott and Boston Scientific. All other authors have no conflicts to declare.
© 2021 Wiley Periodicals LLC.